36 results
424B5
ZYME
Zymeworks Inc.
3 May 24
Prospectus supplement for primary offering
4:17pm
Act, among other things, provides a federal framework for patients to access certain investigational new drug products that have completed a Phase 1 … approval under the FDA expanded access program. While there is no obligation to make product candidates
S-11
available to eligible patients as a result
424B5
ZYME
Zymeworks Inc.
3 May 24
Prospectus supplement for primary offering
4:11pm
.
In addition, the U.S. federal Right to Try Act, among other things, provides a federal framework for patients to access certain investigational new … enrolling in clinical trials and without obtaining FDA approval under the FDA expanded access program. While there is no obligation to make product candidates
8-K
EX-10.1
y35pgf 9jr
26 Dec 23
Zymeworks Announces $50 Million Private Placement to EcoR1 Capital
8:09am
DEFA14A
ikh33 73aeijn3
26 Oct 23
Additional proxy soliciting materials
4:19pm
8-K
EX-10.1
r51daz
18 May 23
Zymeworks Announces Departure of Neil Klompas, President and Chief Operating Officer
8:40am
8-K
EX-10.1
n275wt98
16 May 23
Entry into a Material Definitive Agreement
8:30am
424B5
jvg4iy ngts
8 May 23
Prospectus supplement for primary offering
5:19pm
424B5
gh4gfa9g0f8x
8 May 23
Prospectus supplement for primary offering
5:18pm
8-K
EX-99.1
jho5q9s p5799
10 Apr 23
Zymeworks Announces Appointment of Derek J. Miller to its Board of Directors
4:46pm
8-K
EX-99.1
c8bgw8lpnqjjbk
19 Dec 22
Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab
7:15am